WO2000062813A3 - Lipides peg cationiques et méthodes d'utilisation - Google Patents
Lipides peg cationiques et méthodes d'utilisation Download PDFInfo
- Publication number
- WO2000062813A3 WO2000062813A3 PCT/CA2000/000451 CA0000451W WO0062813A3 WO 2000062813 A3 WO2000062813 A3 WO 2000062813A3 CA 0000451 W CA0000451 W CA 0000451W WO 0062813 A3 WO0062813 A3 WO 0062813A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid
- cationic
- lipids
- methods
- cpls
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU40962/00A AU783647B2 (en) | 1999-04-20 | 2000-04-20 | Cationic peg-lipids and methods of use |
JP2000611949A JP5117648B2 (ja) | 1999-04-20 | 2000-04-20 | カチオン性peg脂質および使用方法。 |
EP00920309A EP1173600A2 (fr) | 1999-04-20 | 2000-04-20 | Lipides peg cationiques et m thodes d'utilisation |
CA002370690A CA2370690A1 (fr) | 1999-04-20 | 2000-04-20 | Lipides peg cationiques et methodes d'utilisation |
AU5454801A AU5454801A (en) | 2000-04-20 | 2001-04-20 | Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers |
EP01927519A EP1355670A2 (fr) | 2000-04-20 | 2001-04-20 | Procedes permettant d'ameliorer la transfection a mediation splp (particule plasmide-lipide stabilisee) au moyen de destabilisateurs de la membrane endosomale |
US09/839,707 US7189705B2 (en) | 2000-04-20 | 2001-04-20 | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
AU2001254548A AU2001254548B2 (en) | 2000-04-20 | 2001-04-20 | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane |
PCT/CA2001/000555 WO2001080900A2 (fr) | 2000-04-20 | 2001-04-20 | Procedes permettant d'ameliorer la transfection a mediation splp (particule plasmide-lipide stabilisee) au moyen de destabilisateurs de la membrane endosomale |
JP2001577996A JP2004508012A (ja) | 2000-04-20 | 2001-04-20 | エンドソーム膜不安定剤を用いたsplp媒介性トランスフェクションの強化方法 |
CA002406654A CA2406654A1 (fr) | 2000-04-20 | 2001-04-20 | Procedes permettant d'ameliorer la transfection a mediation splp (particule plasmide-lipide stabilisee) au moyen de destabilisateurs de la membrane endosomale |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13015199P | 1999-04-20 | 1999-04-20 | |
US60/130,151 | 1999-04-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000062813A2 WO2000062813A2 (fr) | 2000-10-26 |
WO2000062813A3 true WO2000062813A3 (fr) | 2001-08-09 |
Family
ID=22443303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2000/000451 WO2000062813A2 (fr) | 1999-04-20 | 2000-04-20 | Lipides peg cationiques et méthodes d'utilisation |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1173600A2 (fr) |
JP (2) | JP5117648B2 (fr) |
AU (1) | AU783647B2 (fr) |
CA (1) | CA2370690A1 (fr) |
WO (1) | WO2000062813A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
AU5454801A (en) * | 2000-04-20 | 2001-11-07 | Univ British Columbia | Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers |
US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
JP2004511572A (ja) * | 2000-10-25 | 2004-04-15 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 標的化送達のための脂質製剤 |
US6610322B1 (en) * | 2000-12-20 | 2003-08-26 | Brian Charles Keller | Self forming, thermodynamically stable liposomes and their applications |
ATE485031T1 (de) | 2002-06-28 | 2010-11-15 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
WO2004082626A2 (fr) * | 2003-03-18 | 2004-09-30 | Ethicon, Inc. | Diagnostic et traitement faisant appel a un inhibiteur de l'aromatase |
EP2567693B1 (fr) | 2003-07-16 | 2015-10-21 | Protiva Biotherapeutics Inc. | ARN interférents encapsulés dans des lipides |
NZ592917A (en) * | 2003-09-15 | 2012-12-21 | Protiva Biotherapeutics Inc | Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates |
FR2870741B1 (fr) * | 2004-05-25 | 2008-03-14 | Coletica Sa | Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant. |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
US8765181B2 (en) * | 2005-09-09 | 2014-07-01 | Beijing Diacrid Medical Technology Co., Ltd | Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids |
US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US9006191B2 (en) | 2007-12-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering RNA |
WO2009127060A1 (fr) | 2008-04-15 | 2009-10-22 | Protiva Biotherapeutics, Inc. | Nouvelles formulations lipidiques pour l'administration d'acides nucléiques |
JP2011516094A (ja) | 2008-04-15 | 2011-05-26 | プロチバ バイオセラピューティクス インコーポレイティッド | 干渉rnaを用いたcsn5遺伝子発現のサイレンシング方法 |
RU2530555C2 (ru) | 2008-04-17 | 2014-10-10 | ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН | Стимуляция иммунного ответа энантиомерами катионных липидов |
CA2767127A1 (fr) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Formulations lipidiques inedites permettant l'administration d'agents therapeutiques en direction de tumeurs solides |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
WO2011011447A1 (fr) | 2009-07-20 | 2011-01-27 | Protiva Biotherapeutics, Inc. | Compositions et méthodes pour rendre silencieuse lexpression du gène du virus ebola |
WO2011038160A2 (fr) | 2009-09-23 | 2011-03-31 | Protiva Biotherapeutics, Inc. | Compositions et procédés pour réduire au silence des gènes exprimés dans le cancer |
PT2506857T (pt) | 2009-12-01 | 2018-05-14 | Translate Bio Inc | Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas |
WO2011141704A1 (fr) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Nouveaux lipides cationiques cycliques et procédés d'utilisation |
CA2799091A1 (fr) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc. | Lipides cationiques et procedes d'utilisation de ceux-ci |
AU2011268146A1 (en) | 2010-06-17 | 2013-01-10 | Actogenix Nv | Compositions and methods for treating inflammatory conditions |
WO2012000104A1 (fr) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Systèmes non liposomaux pour une administration d'acide nucléique |
TR201910686T4 (tr) | 2011-06-08 | 2019-08-21 | Translate Bio Inc | Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler. |
US11073451B2 (en) | 2011-12-19 | 2021-07-27 | Kode Biotech Limited | Biocompatible method of functionalising substrates with inert surfaces |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
DK2817287T3 (da) | 2012-02-24 | 2019-01-02 | Arbutus Biopharma Corp | Trialkyl kationisk lipid og metoder til anvendelse deraf |
DK2825156T3 (en) * | 2012-03-16 | 2017-10-30 | Merck Patent Gmbh | TARGETED AMINO ACID LIPIDS |
US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
CN105101991A (zh) | 2012-09-21 | 2015-11-25 | Pds生物科技公司 | 改进的疫苗组合物和使用方法 |
EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
PL2968586T3 (pl) | 2013-03-14 | 2019-01-31 | Translate Bio, Inc. | Kompozycje mrna cftr i związne z nimi sposoby i zastosowania |
WO2015011633A1 (fr) | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions et procédés pour l'administration d'arn messager |
EP3060258A1 (fr) | 2013-10-22 | 2016-08-31 | Shire Human Genetic Therapies, Inc. | Thérapie à l'arnm pour la phénylcétonurie |
EP4276176A3 (fr) | 2013-10-22 | 2024-01-10 | Translate Bio, Inc. | Thérapie arnm pour déficience en argininosuccinate synthétase |
EA201691696A1 (ru) | 2014-04-25 | 2017-03-31 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
KR20170075742A (ko) | 2014-10-02 | 2017-07-03 | 프로티바 바이오쎄라퓨틱스, 인코포레이티드 | B형 간염 바이러스 유전자 발현을 제거하는 조성물 및 방법 |
WO2016197132A1 (fr) | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics Inc. | Traitement d'une infection à virus de l'hépatite b à de l'aide de crispr |
CN108350455A (zh) | 2015-07-29 | 2018-07-31 | 阿布特斯生物制药公司 | 用于使b型肝炎病毒基因表达沉默的组合物和方法 |
AU2016312530A1 (en) | 2015-08-24 | 2018-03-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
WO2017083820A1 (fr) | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipides en tant que vecteurs synthétiques pour améliorer le traitement et la présentation de l'antigène ex-vivo en thérapie cellulaire dendritique |
WO2018006052A1 (fr) | 2016-06-30 | 2018-01-04 | Protiva Biotherapeutics, Inc. | Compositions et procédés pour l'administration d'arn messager |
MA47603A (fr) | 2017-02-27 | 2020-01-01 | Translate Bio Inc | Nouvel arnm cftr à codons optimisés |
WO2018213476A1 (fr) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
CA3108544A1 (fr) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Procedes de purification d'arn messager |
GB201910299D0 (en) | 2019-07-18 | 2019-09-04 | Aouadi Myriam | Medical uses, methods and uses |
JP2023508313A (ja) * | 2019-12-20 | 2023-03-02 | サムヤン ホールディングス コーポレイション | ポリ乳酸塩を含む薬物送達用ナノ粒子組成物製造用キット |
AU2021385572A1 (en) | 2020-11-25 | 2023-06-22 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
WO2023144798A1 (fr) | 2022-01-31 | 2023-08-03 | Genevant Sciences Gmbh | Lipides cationiques ionisables pour nanoparticules lipidiques |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998016202A2 (fr) * | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Composition a base de liposomes fusogenes et procede correspondant |
WO1998046208A1 (fr) * | 1997-04-17 | 1998-10-22 | The Regents Of The University Of Michigan | Systeme de delivrance d'adn de follicule pileux |
WO1998051285A2 (fr) * | 1997-05-15 | 1998-11-19 | Genzyme Corporation | Formulations amphiphiles cationiques |
WO1999005094A1 (fr) * | 1997-07-23 | 1999-02-04 | Ribozyme Pharmaceuticals, Incorporated | Nouvelles compositions d'administration de molecules chargees negativement |
WO1999005303A1 (fr) * | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Preparation de particules de lipides-acides nucleiques grace a un procede d'extraction par solvant et d'hydratation directe |
WO1999065461A2 (fr) * | 1998-06-19 | 1999-12-23 | Genzyme Corporation | Complexes micellaires d'amphiphiles cationiques |
WO2000043043A1 (fr) * | 1999-01-21 | 2000-07-27 | Georgetown University | Lipoplexe et polyplexe stabilises selon un procede de post-application d'un ligand-peg dans l'administration ciblee de genes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE265863T1 (de) * | 1995-06-07 | 2004-05-15 | Imarx Pharmaceutical Corp | Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung |
EP0932390A1 (fr) * | 1996-10-11 | 1999-08-04 | Sequus Pharmaceuticals, Inc. | Composition de liposomes therapeutiques et procede |
EP1046394A3 (fr) * | 1999-04-19 | 2001-10-10 | ImaRx Pharmaceutical Corp. | Nouvelles compositions utilisables pour la délivrance de composés dans une cellule |
ATE374785T1 (de) * | 2000-03-02 | 2007-10-15 | Mitsubishi Pharma Corp | Gpib-gebundenes konstrukt und verwendungen davon |
-
2000
- 2000-04-20 WO PCT/CA2000/000451 patent/WO2000062813A2/fr active Application Filing
- 2000-04-20 JP JP2000611949A patent/JP5117648B2/ja not_active Expired - Fee Related
- 2000-04-20 AU AU40962/00A patent/AU783647B2/en not_active Ceased
- 2000-04-20 CA CA002370690A patent/CA2370690A1/fr not_active Abandoned
- 2000-04-20 EP EP00920309A patent/EP1173600A2/fr not_active Withdrawn
-
2012
- 2012-01-31 JP JP2012017765A patent/JP2012122075A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998016202A2 (fr) * | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Composition a base de liposomes fusogenes et procede correspondant |
WO1998046208A1 (fr) * | 1997-04-17 | 1998-10-22 | The Regents Of The University Of Michigan | Systeme de delivrance d'adn de follicule pileux |
WO1998051285A2 (fr) * | 1997-05-15 | 1998-11-19 | Genzyme Corporation | Formulations amphiphiles cationiques |
WO1999005094A1 (fr) * | 1997-07-23 | 1999-02-04 | Ribozyme Pharmaceuticals, Incorporated | Nouvelles compositions d'administration de molecules chargees negativement |
WO1999005303A1 (fr) * | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Preparation de particules de lipides-acides nucleiques grace a un procede d'extraction par solvant et d'hydratation directe |
WO1999065461A2 (fr) * | 1998-06-19 | 1999-12-23 | Genzyme Corporation | Complexes micellaires d'amphiphiles cationiques |
WO2000043043A1 (fr) * | 1999-01-21 | 2000-07-27 | Georgetown University | Lipoplexe et polyplexe stabilises selon un procede de post-application d'un ligand-peg dans l'administration ciblee de genes |
Non-Patent Citations (14)
Title |
---|
ANWER K ET AL: "OPTIMIZATION OF CATIONIC LIPID/DNA COMPLEXES FOR SYSTEMIC GENE TRANSFER TO TUMOR LESIONS", JOURNAL OF DRUG TARGETING,HARWOOD ACADEMIC PUBLISHERS GMBH,DE, vol. 8, no. 2, 2000, pages 125 - 135, XP000951678, ISSN: 1061-186X * |
ARUNA NATHAN ET AL: "COPOLYMERS OF LYSINE AND POLYETHYLENE GLYCOL: A NEW FAMILY OF FUNCTIONALIZED DRUG CARRIERS", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 4, no. 1, 1993, pages 54 - 62, XP000336592, ISSN: 1043-1802 * |
BHATTACHARYA S V ET AL: "Synthesis of novel cationic lipids with oxyethylene spacers at the linkages between hydrocarbon chains and pseudoglyceryl backbone", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 40, no. 46, 12 November 1999 (1999-11-12), pages 8167 - 8171, XP004180445, ISSN: 0040-4039 * |
CHEN TAO ET AL: "Fluorescent-labeled poly(ethylene glycol) lipid conjugates with distal cationic headgroups.", BIOCONJUGATE CHEMISTRY, vol. 11, no. 3, May 2000 (2000-05-01), pages 433 - 437, XP002157295, ISSN: 1043-1802, Retrieved from the Internet <URL:http://pubs.acs.org/CHECKCCIP-979559877/isubscribe/journals/bcches/asap/pdf/bc990171x.pdf> [retrieved on 20000330] * |
HASELGRUBLER T ET AL: "SYNTHESIS AND APPLICATIONS OF A NEW POLY(ETHYLENE GLYCOL) DERIVATIVE FOR THE CROSSLINKING OF AMINES WITH THIOLS", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 6, no. 3, 1 May 1995 (1995-05-01), pages 242 - 248, XP000505483, ISSN: 1043-1802 * |
JAGUR-GRODZINSKI J: "Biomedical application of functional polymers", REACTIVE & FUNCTIONAL POLYMERS,NL,ELSEVIER SCIENCE PUBLISHERS BV, vol. 39, no. 2, 15 February 1999 (1999-02-15), pages 99 - 138, XP004160680, ISSN: 1381-5148 * |
MACIAN M ET AL: "Preliminary studies of the toxic effects of non-ionic surfactants derived from lysine.", TOXICOLOGY, JAN 8 1996, VOL. 106, NO. 1-3, PAGE(S) 1-9, XP000978704 * |
MORI A ET AL: "STABILIZATION AND REGULATED FUSION OF LIPOSOMES CONTAINING A CATIONIC LIPID USING AMPHIPATHIC POLYETHYLENEGLYCOL DERIVATIVES", JOURNAL OF LIPOSOME RESEARCH,US,MARCEL DEKKER, NEW YORK, vol. 8, no. 2, 1 May 1998 (1998-05-01), pages 195 - 211, XP000752693, ISSN: 0898-2104 * |
See also references of EP1173600A2 * |
TRUBETSKOY V S ET AL: "NEW APPROACHES IN THE CHEMICAL DESIGN OF GD-CONTAINING LIPOSOMES FOR USE IN MAGNETIC RESONANCE IMAGING OF LYMPH NODES", JOURNAL OF LIPOSOME RESEARCH,US,MARCEL DEKKER, NEW YORK, vol. 4, no. 2, 1994, pages 961 - 980, XP000619021, ISSN: 0898-2104 * |
TRUBETSKOY V.S. ET AL: "New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes", JOURNAL OF LIPOSOME RESEARCH, 1994, VOL. 4, NO. 2, PAGE(S) 961-983, XP000978705 * |
VESKA TONCHEVAL ET AL: "BLOCK COPOLYMERS WITH pH-DEPENDENT SECONDARYSTRUCTURE", JOURNAL OF CONTROLLED RELEASE, vol. 48, no. 2 - 3, October 1997 (1997-10-01), pages 301 - 302, XP002157296, ISSN: 0168-3659 * |
WEISSIG V ET AL: "Long-circulating gadolinium-loaded liposomes: potential use for magnetic resonance imaging of the blood pool", COLLOIDS AND SURFACES B (BIOINTERFACES), OCT. 2000, ELSEVIER, NETHERLANDS, vol. 18, no. 3-4, pages 293 - 299, XP000971876, ISSN: 0927-7765 * |
ZALIPSKY S ET AL: "LONG CIRCULATING, CATIONIC LIPOSOMES CONTAINING AMINO-PEG-PHOSPHATIDYLETHANOLAMINE", FEBS LETTERS,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM,NL, vol. 353, 1994, pages 71 - 74, XP002920144, ISSN: 0014-5793 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
Also Published As
Publication number | Publication date |
---|---|
JP2012122075A (ja) | 2012-06-28 |
WO2000062813A2 (fr) | 2000-10-26 |
AU4096200A (en) | 2000-11-02 |
CA2370690A1 (fr) | 2000-10-26 |
AU783647B2 (en) | 2005-11-17 |
JP5117648B2 (ja) | 2013-01-16 |
JP2002542341A (ja) | 2002-12-10 |
EP1173600A2 (fr) | 2002-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000062813A3 (fr) | Lipides peg cationiques et méthodes d'utilisation | |
WO2003103822A3 (fr) | Nanocapsules lipidiques indetectables, procedes de preparation de celles-ci et utilisation de ces nanocapsules en tant que support de principe(s) actif(s) | |
WO2003068144A3 (fr) | Agents cytotoxiques supportant une fraction reactive de polyethyleneglycol, conjugues cytotoxiques comprenant des groupes de liaison de polyethyleneglycol et leurs procedes de fabrication et d'utilisation | |
FR2840532B1 (fr) | Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s) | |
WO2000061543A3 (fr) | Esters de l-carnitine ou de l-carnitines alcanoyles utilises comme lipides cationiques pour un apport intracellulaire de composes actifs d'un point de vue pharmacologique | |
WO2000065024A3 (fr) | Micelles polymeriques hyperramifiees destinees a encapsuler et transporter des molecules hydrophobes | |
CA2259179A1 (fr) | Formulations d'emulsions pour des agents actifs hydrophiles | |
WO2002034236A3 (fr) | Formulations de lipides pour une administration ciblee | |
WO2000040203A3 (fr) | Agents d'administration polymeres et composes d'agents d'administration | |
AU1928501A (en) | Formulations for pharmaceutical agents ionizable as free acids or free bases | |
WO2001045796A3 (fr) | Procede de preparation d"esters de 1-benzotriazolyl carbonate de poly(ethylene glycol) | |
WO2003000233A3 (fr) | Liberation de petites molecules hydrophiles comprises dans des vesicules lipidiques | |
WO1998038984A3 (fr) | Preparations d'agents pharmaceutiques hydrophobes | |
WO2002097116A3 (fr) | Systeme de delivrance d'acides nucleiques | |
WO2002038105A3 (fr) | Nouveaux conjugues d'acide amine et d'analogues de polyamine utiles en tant qu'agents anticancer | |
CA2252055A1 (fr) | Liposomes entrainant une fusion | |
CA2196780A1 (fr) | Systeme d'administration liposomique comprenant des lipopolyamines cationiques et des lipides neutres pour l'administration d'agents biologiquements actifs | |
WO2005070466A3 (fr) | Composition de liposomes pour l'administration d'agents therapeutiques | |
AU2102101A (en) | Use of cationic lipids for intracellular protein delivery | |
WO2003045306A3 (fr) | Composes phenoxy amine et compositions pour administrer des principes actifs | |
WO2002036161A3 (fr) | Nouvelles compositions ciblees a usage diagnostique ou therapeutique | |
EP2452684A3 (fr) | Micelles | |
WO1999047101A3 (fr) | Compositions contenant des acides lysophosphatidiques qui inhibent l'apoptose et leurs utilisations | |
WO2002060929A3 (fr) | Conjugues polymeres de neublastine et methodes d'utilisation a | |
WO2001095884A3 (fr) | Preparations d'inhibiteurs de benzoquinazoline thymidylate synthase en liposomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2370690 Country of ref document: CA Kind code of ref document: A Country of ref document: CA Ref document number: 2000 611949 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000920309 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000920309 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |